PMID- 12506021
OWN - NLM
STAT- MEDLINE
DCOM- 20030620
LR  - 20210206
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 101
IP  - 9
DP  - 2003 May 1
TI  - Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: 
      an alternative to IVIG.
PG  - 3708-13
AB  - Intravenous immunoglobulin (IVIG) is used to treat immune thrombocytopenia 
      resulting from a variety of autoimmune and nonautoimmune diseases such as 
      idiopathic thrombocytopenic purpura (ITP), heparin-induced thrombocytopenia, and 
      posttransfusion purpura. IVIG is a limited resource and although considered safe, 
      may nevertheless carry some risk of transferring disease. Its high cost makes 
      monoclonal antibodies, capable of mimicking the clinical effects of IVIG, highly 
      desirable. We show here, using a murine model of ITP, that selected monoclonal 
      antibodies can protect against thrombocytopenia. SCID mice were pretreated with 1 
      of 21 monoclonal antibodies before induction of thrombocytopenia by antiplatelet 
      antibody. Four antibodies reacted with the CD24 antigen on erythrocytes. Two 
      antibodies were of the IgM class, and although one IgM antibody caused a minimal 
      degree of anemia (P <.05), neither antibody ameliorated immune thrombocytopenia. 
      One of 2 anti-CD24 antibodies of the IgG class ameliorated immune 
      thrombocytopenia and blocked reticuloendothelial system function at the same 
      doses that protected against thrombocytopenia. Some antibodies reactive with 
      other circulating cell types also protected against immune-mediated 
      thrombocytopenia while no antibody without a distinct target antigen in the mice 
      was protective. Protective monoclonal antibodies significantly prevented 
      thrombocytopenia at down to a 1000-fold lower dose (200 microg/kg) as compared 
      with standard IVIG treatment (2 g/kg). It is concluded that monoclonal IgG with 
      specificity for a circulating cellular target antigen may provide an alternative 
      therapeutic approach to treating immune thrombocytopenia.
FAU - Song, Seng
AU  - Song S
AD  - Transfusion Medicine Research and the Department of Laboratory Medicine and 
      Pathobiology, St Michael's Hospital, Toronto, ON, Canada.
FAU - Crow, Andrew R
AU  - Crow AR
FAU - Freedman, John
AU  - Freedman J
FAU - Lazarus, Alan H
AU  - Lazarus AH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20021227
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, CD)
RN  - 0 (CD24 Antigen)
RN  - 0 (Cd24a protein, mouse)
RN  - 0 (Hyaluronan Receptors)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Isoantibodies)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Receptors, IgG)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/immunology/*therapeutic use
MH  - Antibody Specificity
MH  - Antigens, CD/*immunology
MH  - Autoimmune Diseases/prevention & control/*therapy
MH  - Blood Platelets/immunology
MH  - CD24 Antigen
MH  - Disease Models, Animal
MH  - Drug Evaluation, Preclinical
MH  - Erythrocytes/*immunology
MH  - Female
MH  - Germ-Free Life
MH  - Hyaluronan Receptors/immunology
MH  - Immunoglobulin G/immunology/*therapeutic use
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Isoantibodies/toxicity
MH  - *Membrane Glycoproteins
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, SCID
MH  - Mononuclear Phagocyte System/drug effects/immunology
MH  - Purpura, Thrombocytopenic, Idiopathic/prevention & control/*therapy
MH  - Receptors, IgG/immunology
EDAT- 2002/12/31 04:00
MHDA- 2003/06/21 05:00
CRDT- 2002/12/31 04:00
PHST- 2002/12/31 04:00 [pubmed]
PHST- 2003/06/21 05:00 [medline]
PHST- 2002/12/31 04:00 [entrez]
AID - S0006-4971(20)50759-3 [pii]
AID - 10.1182/blood-2002-10-3078 [doi]
PST - ppublish
SO  - Blood. 2003 May 1;101(9):3708-13. doi: 10.1182/blood-2002-10-3078. Epub 2002 Dec 
      27.